Search Results - "Szapary, P."

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up by Papp, K.A., Griffiths, C.E.M., Gordon, K., Lebwohl, M., Szapary, P.O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P.D., Strober, B., Reich, K.

“…Summary Background  Long‐term safety evaluations of biologics are needed to inform patient management decisions. Objectives  To evaluate the safety of…”
Get full text

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years by Kimball, A.B., Gordon, K.B., Fakharzadeh, S., Yeilding, N., Szapary, P.O., Schenkel, B., Guzzo, C., Li, S., Papp, K.A.

“…Summary Background  An unmet need remains for safe and effective long‐term treatments of psoriasis. Objectives  To evaluate ustekinumab efficacy and safety for…”
Get full text

Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up by Langley, R.G., Lebwohl, M., Krueger, G.G., Szapary, P.O., Wasfi, Y., Chan, D., Hsu, M.C., You, Y., Poulin, Y., Korman, N., Prinz, J.C., Reich, K.

“…Summary Background Evaluation of the dosing flexibility and long‐term efficacy of biological agents is limited. Objectives To evaluate the long‐term efficacy…”
Get full text

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study by Kimball, A.B., Papp, K.A., Wasfi, Y., Chan, D., Bissonnette, R., Sofen, H., Yeilding, N., Li, S., Szapary, P., Gordon, K.B.

“…Background  Ongoing evaluation of biological agents in patients with moderate‐to‐severe psoriasis is needed to support their long‐term use. Objective  To…”
Get full text

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection by Tsai, T.-F., Ho, V., Song, M., Szapary, P., Kato, T., Wasfi, Y., Li, S., Shen, Y.K., Leonardi, C.

“…Summary Background  Ustekinumab is a monoclonal antibody that targets interleukin (IL)‐12/23 p40 to treat psoriasis. The IL‐12 pathway is also important in…”
Get full text

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies by Reich, K., Langley, R.G., Lebwohl, M., Szapary, P., Guzzo, C., Yeilding, N., Li, S., Hsu, M-C., Griffiths, C.E.M.

“…Summary Background  Patients with psoriasis are believed to be at an increased risk of cardiovascular (CV) morbidity, and the effect of biological agents on CV…”
Get full text

Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials by Guenther, L., Han, C., Szapary, P., Schenkel, B., Poulin, Y., Bourcier, M., Ortonne, J.P., Sofen, H.L.

“…Background  Ustekinumab, a human anti‐interleukin‐12/23 monoclonal antibody, has been shown to effectively treat moderate‐to‐severe psoriasis which…”
Get full text

Physicians recommendations for and personal use of low-fat and low-carbohydrate diets by La Puma, J, Szapary, P, Maki, K C

Get full text

Pharmacological management of high triglycerides and low high-density lipoproetin cholesterol by Szapary, Philippe O, Rader, Daniel J

“…Elevated serum trigylcerides and low high-density lipoprotein (HDL) cholesterol are part of a metabolic syndrome that is increasingly being recognized as an…”
Get full text

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis by Sands, Bruce E, Sandborn, William J, Panaccione, Remo, O’Brien, Christopher D, Zhang, Hongyan, Johanns, Jewel, Adedokun, Omoniyi J, Li, Katherine, Peyrin-Biroulet, Laurent, Van Assche, Gert, Danese, Silvio, Targan, Stephan, Abreu, Maria T, Hisamatsu, Tadakazu, Szapary, Philippe, Marano, Colleen

“…Patients with moderate-to-severe ulcerative colitis were randomly assigned to receive placebo or induction doses of ustekinumab. Patients who had a response to…”
Get full text

Effects of Pioglitazone on Lipoproteins, Inflammatory Markers, and Adipokines in Nondiabetic Patients with Metabolic Syndrome by Szapary, Philippe O, Bloedon, LeAnne T, Samaha, Frederick F, Duffy, Danielle, Wolfe, Megan L, Soffer, Daniel, Reilly, Muredach P, Chittams, Jesse, Rader, Daniel J

“…OBJECTIVE—The purpose of this research was to evaluate the short-term effects of pioglitazone (PIO) on high-density lipoprotein cholesterol (HDL-C) and other…”
Get full text

PCN107 Economic Burden of Complications Associated with Transthoracic Needle Biopsy of Pulmonary Nodules: A Retrospective Cohort Analysis by Vachani, A., Zhou, M., Johnston, S., Ghosh, S., Zhang, S., Szapary, P., Gaurav, D., Kalsekar, I.

Get full text

Body mass and hypertension in women by Oler, A, Szapary, P

Get full text

P477 Clinical remission by legacy vs. FDA definitions: definition justification and results from UNIFI Study by Sandborn, W J, Strauss, R, Zhang, H, Johanns, J, Szapary, P, Marano, C, Danese, S

“…Abstract Background Ustekinumab (UST), an interleukin-12/23 blocker, was evaluated as induction and maintenance for moderate–severe ulcerative colitis (UC)…”
Get full text

P406 General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies by Danese, S, Sands, B E, Leong, R W, Zhang, H, Johanns, J, Szapary, P, Marano, C, Han, C

“…Abstract Background The UNIFI studies evaluated the safety and efficacy of ustekinumab (UST) intravenous (IV) induction and subcutaneous (SC) maintenance in…”
Get full text

P681 Ustekinumab therapy induced clinically meaningful improvement and remission as measured by the Inflammatory Bowel Disease Questionnaire: Results from the phase 3 UNIFI induction and maintenance studies by Sands, B E, Han, C, Zhang, H, Johanns, J, Szapary, P, Marano, C, Leong, R W, Danese, S

“…Abstract Background The UNIFI studies evaluated the safety and efficacy of ustekinumab (UST) intravenous (IV) induction and subcutaneous (SC) maintenance in…”
Get full text

OP37 Efficacy and safety of ustekinumab as maintenance therapy in ulcerative colitis: Week 44 results from UNIFI by Sandborn, W J, Sands, B E, Panaccione, R, O’Brien, C D, Zhang, H, Johanns, J, Peyrin-Biroulet, L, Van Assche, G, Danese, S, Targan, S R, Abreu, M T, Hisamatsu, T, Szapary, P, Marano, C

“…Abstract Background The study objective was to evaluate the safety and efficacy of SC ustekinumab (UST) as maintenance therapy in UC patients who were in…”
Get full text

DOP47 Sustained remission in patients with moderate to severe ulcerative colitis: Results from the Phase 3 UNIFI maintenance study by Van Assche, G, Targan, S R, Baker, T, O’Brien, C D, Zhang, H, Johanns, J, Szapary, P, Marano, C, Leong, R W, Rowbotham, D, Hisamatsu, T, Danese, S, Sands, B E, Peyrin-Biroulet, L

“…Abstract Background The UNIFI randomised-withdrawal maintenance study evaluated the safety and efficacy of subcutaneous (SC) ustekinumab in patients with…”
Get full text

DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial by Danese, S, Sands, B E, O'Brien, C D, Zhang, H, Johanns, J, Sloan, S, Izanec, J, Szapary, P, Marano, C, Leong, R W, Rowbotham, D, Targan, S R, Van Assche, G

“…Abstract Background The objective was to evaluate the efficacy and safety of ustekinumab (UST) through Week 16 induction among patients with moderate–severe UC…”
Get full text

P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI by Sands, B E, Peyrin-Biroulet, L, Marano, C, O'Brien, C D, Zhang, H, Johanns, J, Szapary, P, Rowbotham, D, Leong, R W, Arasaradnam, R P, Danese, S, Van Assche, G, Targan, S, Sandborn, W J

“…Abstract Background Ustekinumab (UST), an IL12/23 blocker approved for Crohn’s disease, was effective in Ph3 induction and maintenance of moderate–severe…”
Get full text